RomiDEPsin

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 787 publications

Ford JG, Koh MJ, Lenart AW, et al. Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas. Blood Adv. 2025;9(16):4286-4305.

Ford JG, Koh MJ, Lenart AW, et al. Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas. Blood Adv. 2025;9(16):4286-4305.

Journal: Blood advances

Published: January 29, 2026

Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database.

Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database.

Journal: Journal of pharmaceutical health care and sciences

Published: January 27, 2026

Clinical revival of romidepsin with nanoparticles.

Clinical revival of romidepsin with nanoparticles.

Journal: Blood

Published: December 04, 2025

A phase 1 trial of romidepsin, azacitidine, dexamethasone and lenalidomide in relapsed or refractory T-cell lymphoma.

A phase 1 trial of romidepsin, azacitidine, dexamethasone and lenalidomide in relapsed or refractory T-cell lymphoma.

Journal: Blood advances

Published: November 24, 2025

In Vitro and In Vivo Efficacy of Romidepsin Alone and in Addition to Standard of Care for Treatment of Ewing Sarcoma.

In Vitro and In Vivo Efficacy of Romidepsin Alone and in Addition to Standard of Care for Treatment of Ewing Sarcoma.

Journal: Cancers

Published: November 12, 2025

Data-Driven Drug Discovery Optimization for Breast Cancer Using Interpretable Machine Learning Models.

Data-Driven Drug Discovery Optimization for Breast Cancer Using Interpretable Machine Learning Models.

Journal: Journal of visualized experiments : JoVE

Published: September 29, 2025

Vesiculobullous Eruption in Patient With Mycosis Fungoides.

Vesiculobullous Eruption in Patient With Mycosis Fungoides.

Journal: The American Journal of dermatopathology

Published: September 23, 2025

A real-world retrospective study of romidepsin: Insights from the Food and Drug Administration Adverse Event Reporting System.

A real-world retrospective study of romidepsin: Insights from the Food and Drug Administration Adverse Event Reporting System.

Journal: Medicine

Published: September 09, 2025

Cross-resistance of Belinostat and Romidepsin in Non-T Follicular Helper Peripheral T-cell Lymphoma Models Suggests Subtype-Specific Implications for Belinostat-CHOP.

Cross-resistance of Belinostat and Romidepsin in Non-T Follicular Helper Peripheral T-cell Lymphoma Models Suggests Subtype-Specific Implications for Belinostat-CHOP.

Journal: Molecular cancer therapeutics

Published: August 11, 2025

Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphoma.

Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphoma.

Journal: Leukemia & lymphoma

Published: August 11, 2025

Targeting histone deacetylation, cell cycle regulators and heat shock proteins as novel therapeutic strategies for penile cancers.

Targeting histone deacetylation, cell cycle regulators and heat shock proteins as novel therapeutic strategies for penile cancers.

Journal: NPJ precision oncology

Published: August 07, 2025

Coexistence of Mycosis Fungoides and Photosensitive or Autoimmune Diseases. The Therapeutic Challenge: A retrospective Case Series from a Tertiary Referral Center.

Coexistence of Mycosis Fungoides and Photosensitive or Autoimmune Diseases. The Therapeutic Challenge: A retrospective Case Series from a Tertiary Referral Center.

Journal: The Israel Medical Association journal : IMAJ

Published: June 30, 2025

Showing 1-12 of 787

Last Updated: 04/28/2026